Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma

Abstract

DLL3 is selectively and homogeneously expressed in <i>IDH</i>-mutant gliomas and can be targeted with Rova-T in patient-derived <i>IDH</i>-mutant glioma tumorspheres. Our findings are potentially immediately translatable and have implications for therapeutic strategies that exploit cell surface tumor-associated antigens.